posted
Like the potential for this one going forward, reversal back up.
This one came up on my screener today, company has 2 major products. The workstation and the lassete. Work station sales were weak last quarter so, i assuming why company the stock price fell. The workstation has a profit margin >50%, but not enough units sold last year to really boost revenue stream.
The product which i think has the most potential in the healthcare industry is the lassette.The company introduced the product in Nov at the AABB (American Association of Blood Banks) and expects significant revenue streams from this product being sold to bloodbanks, then eventually other health care venues.
Technicals are a go, and this is bottom reversal. Volume, precedes run, macd rsi adx crosses and ma crosses. Shares outstanding from my due diligence around 23mil, revenue target this year roughly 3-4 mil, debt around 1.3 mil. Expect profitabily by years end.
Short term top .42 intermediate 1.00+range .42 needs to broken ..see 3yr chart.
aimho do your dd see charts.
Posts: 309 | Registered: Nov 2004
| IP: Logged |
posted
Cell Robotics Enters Blood Bank Market with New Lasette, Helps Increase World's Blood Supply ALBUQUERQUE, N.M., November 4, 2004 -- Cell Robotics International Inc. (OTC BB: CRII) announced today that it anticipates significant sales of its proprietary Lasette product to the blood banking community based on the product's reception at the 2004 annual meeting of the American Association of Blood Banks in Baltimore last week. The Lasette instrument provides specific and significant advantages for blood donor screening resulting in greater availability of donors as described in a paper presented to the AABB membership.
"We are overwhelmed by the tremendous response from the worldwide blood banking community," said Gary Oppedahl, "During the AABB trade exposition we conducted product demonstrations almost every 60 seconds for the entire three days. You wouldn't think that people would wait in line for 20 minutes just to have their fingers lanced."
"The Lasette is definitely the most exciting new technology exhibited at this meeting in a long while," said Sheri Goertzen of Children's Hospital of Central California.
The Company's Lasette is a small device that uses a tiny laser beam for collection of capillary blood samples. United Blood Systems (UBS), the second largest blood collection agency in the U.S., has studied application of the Lasette in blood donor screening over the last 13 months. The results of these studies indicate that the Lasette can provide more accurate anemia screening results that are required from volunteer donors prior to blood donation.
"What [the Lasette] does is it provides a better sample for us to determine whether or not someone has enough blood cells to give a pint away" says Elizabeth Waltman, executive director of the UBS' Albuquerque operations. 12% of volunteer donors are turned away, or deferred, due to screening tests. According to study data, the Lasette practically eliminates erroneous deferrals from poor capillary blood samples, increasing the availability of donated blood supply.
Conventional steel lancets leave injured tissue in the skin when creating the wound for blood collection. In contrast, the Lasette removes injured tissue from the skin by laser ablation, similar to the effect of cosmetic laser surgery. The Lasette produces cleaner, better blood samples over longer periods of time, and without coagulation that can lead to errors in screening test results. In addition, the fingers are not sore as they often are after the procedure and the absence of disposable needles eliminates the danger of health care workers or patients accidentally being stuck by a contaminated device.
These results on donor refusal rates and donor satisfaction are a windfall for blood banks and plasma centers. The addition of more qualified donors based on the Lasette blood screening results creates a significant return on investment for blood banks without significantly changing the current costs. This impact on deferral rates has far-reaching implications for blood banks around the world providing preferred and rapid access to a tens of million dollar market with substantial potential for recurring revenues. About 25 million pre-donation blood tests are performed each year in the U.S. alone. The Company expects the enthusiasm of the blood banking community to spread to other blood banks and clinical institutions in the United States and abroad.
The Lasette uses a pulse of infrared laser light to ablate a small wound in the patient's fingertip to establish capillary blood access. The procedure requires no physical penetration of the skin and completely eliminates the use of medical sharps for blood collection. After months of product development the company released the newly designed Lasette model P200 in July. The P200 is designed specifically for fast and easy collection of capillary samples for blood chemistry screening and clinical applications. The Company will now aggressively introduce the P200 to the clinical market, and expects that introduction of the technology through hospital-based blood banks will stimulate consideration by other clinical departments. The P200 is ideal for all clinical applications with equally good value propositions for prison infirmaries, where the absence of sharps is of primary importance and nursing homes, where the reduction of pain and absence of soreness is very important to seniors and their health care providers. The successful launch into Blood Banks represents a well-executed first step.
In the past year, despite having very limited resources to conduct its operations, the Company was able to implement manufacturing improvements and reductions in overall company expenditures, along with design changes and successful negotiations with our vendors which have lowered the costs of the Lasette to the Company by 35% with expected further reductions as volumes increase.
Cell Robotics International, Inc., is a medical laser products company. For further information, please visit the Company's web site at www.cellrobotics.com or www.Lasette.com .
This press release includes certain statements that may be deemed to be "forward-looking statements'' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 as amended. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are "forward-looking statements." Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; risks associated with the development of new products and markets; general competitive factors; the Company's ability to execute its service and product sales plans; the impact of current and future laws and government regulation, as well as repeal or modification of same, affecting the medical device industry and the Company's operations in particular; adequacy of our financial resources; obtaining and maintaining regulatory approval; the ability to retain key personnel and the risks described from time to time in the Company's Securities and Exchange Commission (SEC) filings. For all these reasons, actual results or developments may differ materially from those projected in the "forward-looking statements."
Back to 2004 Press Releases
Posts: 309 | Registered: Nov 2004
| IP: Logged |
posted
Cool, thanks, seems to be the bottom. This stock looks to have been beaten down pretty good. I'm in, and will be getting more tomorrow.
Posts: 7 | Registered: Jan 2005
| IP: Logged |
posted
Good bottom play here. I picked some up earlier today. It is a nice chart. Gotta love finding stocks that are beaten down and have been ignored, especially with rumors of good news coming.
-------------------- FurrySound -DD-GLTA-Unless I've quoted a source, I know not what I speak of. YahooIM=FurrySound Posts: 2170 | From: Pennsylvania, USA | Registered: Mar 2004
| IP: Logged |
quote:Originally posted by pirateofwallst: .....Technicals are a go, and this is bottom reversal. Volume, precedes run, macd rsi adx crosses and ma crosses. Shares outstanding from my due diligence around 23mil, revenue target this year roughly 3-4 mil, debt around 1.3 mil. Expect profitabily by years end.
Short term top .42 intermediate 1.00+range .42 needs to broken ..see 3yr chart.
Grabbed 1st position today @.15 - looks like I caught this 1 at a decent price before the run. Tomorrow might grab my 2nd position - looking very bullish for momentum to take over. Check out RSI - about to cross 50 line. Looks like 50dma is .21? Should set off alerts when it crosses....then off to the races!Posts: 323 | Registered: May 2004
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Big Grin]](biggrin.gif)
